Lillie James Woodruff 4
4 · MapLight Therapeutics, Inc. · Filed May 6, 2026
Research Summary
AI-generated summary of this filing
MapLight Therapeutics (MPLT) CSO Lillie James Woodruff Sells Shares
What Happened
Lillie James Woodruff, Chief Scientific Officer of MapLight Therapeutics (MPLT), sold a total of 51,707 shares in open-market transactions between May 4 and May 6, 2026 for aggregate proceeds of about $1,468,252. Sales by date:
- May 4, 2026 — 15,801 shares (9,250 @ $27.50; 5,526 @ $28.37; 320 @ $29.56; 705 @ $30.08) — $441,813 total.
- May 5, 2026 — 11,095 shares (10,132 @ $28.12; 963 @ $29.00) — $312,839 total.
- May 6, 2026 — 24,811 shares (8,390 @ $28.04; 16,421 @ $29.13) — $713,600 total.
All transactions are coded “S” (sale). Sales are generally routine liquidity events and do not by themselves indicate company prospects.
Key Details
- Transaction dates: May 4–6, 2026; Form 4 filed May 6, 2026 (appears timely—within typical 2‑business‑day reporting window).
- Total shares sold: 51,707; total proceeds: ~$1.47 million.
- Shares owned after transaction: Not specified in the provided filing excerpt.
- Notable footnotes: F1 indicates one or more trades were made pursuant to a Rule 10b5‑1 trading plan adopted Dec 29, 2025. Footnotes F2–F9 note that reported prices are weighted averages across multiple execution prices (ranges provided) and that the filer can supply per‑price detail on request.
- Transaction code: S = Sale (no purchases, exercises, or awards reported here).
Context
- A Rule 10b5‑1 plan means some trades were pre‑scheduled under an approved plan (helps show trades were pre‑arranged, not necessarily based on inside information).
- Sales are common for personal liquidity, tax or diversification reasons; purchases are typically seen as a stronger signal of insider confidence.
- This summary is factual and does not speculate on the insider’s motives. If you need the exact per‑trade execution prices within the weighted averages, the filer has offered to provide that breakdown on request.
Insider Transaction Report
Form 4
Lillie James Woodruff
Chief Scientific Officer
Transactions
- Sale
Voting Common Stock
[F1][F2]2026-05-04$27.50/sh−9,250$254,375→ 285,907 total - Sale
Voting Common Stock
[F1][F3]2026-05-04$28.37/sh−5,526$156,773→ 280,381 total - Sale
Voting Common Stock
[F1][F4]2026-05-04$29.56/sh−320$9,459→ 280,061 total - Sale
Voting Common Stock
[F1][F5]2026-05-04$30.08/sh−705$21,206→ 279,356 total - Sale
Voting Common Stock
[F1][F6]2026-05-05$28.12/sh−10,132$284,912→ 269,224 total - Sale
Voting Common Stock
[F1][F7]2026-05-05$29.00/sh−963$27,927→ 268,261 total - Sale
Voting Common Stock
[F1][F8]2026-05-06$28.04/sh−8,390$235,256→ 259,871 total - Sale
Voting Common Stock
[F1][F9]2026-05-06$29.13/sh−16,421$478,344→ 243,450 total
Footnotes (9)
- [F1]This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.84 to $27.835 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.845 to $28.74 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.9669 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.55 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.755 to $28.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F7]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.79 to $29.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F8]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.675 to $28.6587 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F9]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.71 to $29.57 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Signature
/s/ Kristopher L. Hanson, Attorney-in-Fact|2026-05-06